{"id":"NCT03639675","sponsor":"Bayer","briefTitle":"Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied","officialTitle":"A Single-arm, Non-randomized and Open-label Phase 3 Study Evaluating the Efficacy, Safety and Tolerability of Intravitreal Aflibercept in Japanese Patients With Neovascular Glaucoma (NVG)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-03","primaryCompletion":"2019-02-14","completion":"2019-03-14","firstPosted":"2018-08-21","resultsPosted":"2020-02-18","lastUpdate":"2020-03-03"},"enrollment":16,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Glaucoma, Neovascular"],"interventions":[{"type":"DRUG","name":"Aflibercept (EYLEA, BAY86-5321)","otherNames":[]},{"type":"DRUG","name":"Topical IOP-lowering drugs","otherNames":[]}],"arms":[{"label":"NVG patients","type":"EXPERIMENTAL"}],"summary":"The researchers in this trial want to learn how the drug aflibercept works in in Japanese patients with increased eye pressure that is caused by new blood vessels growing in the eye (neovascular glaucoma or NVG). They also want to find out how patient tolerate the application of the drug that is injected in the vitreous humor of the eye and if this will cause any medical problems during the trial (vitreous humor, also called vitreous body is the clear gel that fills the space between the lens and the retina of the eyeball).","primaryOutcome":{"measure":"Change in Intraocular Pressure (IOP) From Baseline to Week 1","timeFrame":"Baseline and week 1","effectByArm":[{"arm":"Aflibercept 2 mg Intravitreal (IVT) Injection Group","deltaMin":-8.3,"sd":7.3}],"pValues":[{"comp":"OG000","p":"0.0004"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":7,"countries":["Japan"]},"refs":{"pmids":["33330959"],"seeAlso":["https://clinicaltrials.bayer.com/"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":16},"commonTop":["Eye pain","Corneal erosion","Eye pruritus","Nasopharyngitis","Pneumonia"]}}